TNF and rheumatoid arthritis: Certolizumab has been extensively studied in randomized clinical trials in RA patients who did not respond to disease-modifying antirheumatic drugs (DMARDs) [7–11], were naive to these agents [12–14] or did not respond to other anti-TNFα agents [15,16].